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Abstract 
 
Modification of the cap group of biphenylacrylohydroxamic acid-based HDAC inhibitors led to the 
identification of a new derivative (3) characterized by an indolyl-substituted 4-phenylcinnamic 
skeleton. Molecular docking was used to predict the optimal conformation in the class I HDACs 
active site. Compound 3 showed HDAC inhibitory activity and antiproliferative activity against a 
panel of tumor cell lines, in the low µM range. The compound was further tested in vitro for 
acetylation of histone H4 and other non-histone proteins, and in vivo in a colon carcinoma model, 
showing significant proapoptotic and antitumor activities. 
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1. Introduction  
 
Inappropriate epigenetic modifications of gene expression are associated with malignant phenotype 
and tumor progression. Regulation of gene expression is mediated by several mechanisms such as 
DNA methylation [1], ATP-dependent chromatin remodeling [2], and post-translational 
modifications of histones [3,4]. The latter mechanism includes dynamic acetylation and 
deacetylation of lysine amino residues present in the tail of core histones. Enzymes responsible for 
the reversible acetylation/deacetylation processes are histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), respectively [5].  
Being implicated in silencing of critical regulatory pathways, including proapoptotic programs, 
HDACs have recently gained prominence as an emerging class of anticancer targets [6]. 
Eighteen mammalian HDAC enzymes have been identified so far, which can be subdivided into 
four classes according to a cofactor (Zn2+ for Classes I, II and IV or NAD+ for Class III) [7]. 
A widely accepted pharmacophore model for HDAC inhibitors consists of a metal binding head 
group, a linker domain and a cap group, which interacts with the residues on the rim of the active 
site [7]. 
Recently, we have synthesized a series of hydroxamic acid-based compounds, characterized by a 
biphenyl-4-yl-acrylohydroxamic acid skeleton (compounds 1, Figure 1) [8]. The compounds were 
designed based on the hypothesis that the proximal phenyl ring, extended from the hydroxamic acid 
via a double bond, could be suitable to occupy the narrow tube-like pocket of the HDAC active site. 
In our model, the distal phenyl ring of 1 (cap moiety) appeared to be accommodated in a large 
cavity, without a significant steric clash. Indeed, crystal structures of HDAC enzymes show 
multiple grooves on the surface of the protein around the binding site and cap groups are in a 
position suitable to interact with these grooves [9]. Thus, modification of the cap group appeared 
the most promising strategy to optimize drug-target interactions.  
 
On the basis of these findings, over the last few years we have conducted an extensive research on 
the cap modification of our compounds, with the aim to discover novel HDAC inhibitors with high 
potency and enhanced interactions within the HDACs active site [10,11].  
The introduction of an oxime group on the cinnamic skeleton gave 4-oxime-cinnamoyl 
hydroxamates endowed with promising inhibitory activity on HDAC6 and HDAC8 coupled to a 
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good selectivity profile [11]. Further attempts to modify the cap group with the incorporation of an 
adamantyl moiety led to a substantial reduction of inhibitory activity toward the tested enzymes 
[10].  
In continuation of these efforts, we developed two new structures with modifications on the 
biphenyl system (compounds 2 and 3). Whereas in 2 we wanted to investigate the impact of the 
presence of a linker between the two rings on HDAC activity, in compound 3 an indole fragment 
was installed on the biphenyl system. The presence of this group has been recently associated with 
potent HDAC inhibition, mainly for nuclear HDACs 1 and 3 [12] and, differently from the 
adamantyl moiety, [10] could work as a versatile scaffold for further functionalization. 
Here we show the HDAC inhibitory activity of the new compounds, both active in the low µM 
range. The synthesis and the evaluation of their biological activity are also reported. 
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Fig.1. Structures of phenylacrylohydroxamic acids 
 
2. Results and discussion 
 
2.1 Chemistry 
 
The synthesis of compound 2 started from the condensation of 4-bromobenzophenone 4 with 
acetone under McMurry conditions [13] to obtain 1-bromo-4-(2-methyl-1-phenylprop-1-
enyl)benzene (5). Heck coupling with methyl acrylate afforded 6 in 40% yield. Treatment of the 
ester 6 with O-tetrahydropyranylhydroxylamine gave 7, which was converted into the desired 
hydroxamic acid 2 by reaction with p-toluenesulfonic acid in methanol (Scheme 1).  
Compound 3 was synthesized starting from the N-Boc-protected 3-formyl-2-methylindole 8, which 
was reacted with (2-bromobenzyl)triphenylphosphonium bromide 9 to give compound 10. Suzuki 
coupling with 4-formylphenylboronic acid afforded the aldehyde 11. Wittig reaction, followed by 
 4
removal of the Boc protecting group and ester hydrolysis gave 14. Treatment of the acid with 
hydroxylamine hydrochloride afforded the hydroxamic acid 3 (Scheme 2).  
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Scheme 1. Synthesis of compound 2. Reagents and conditions: a) acetone, TiCl4, Zn, dry THF, reflux, 2.5 h, 
71%; b) methylacrylate, Pd(CH3COO)2, tri(o-tolyl)phosphine, triethylamine, reflux, 3 h, 40%; c) O-
tetrahydropyranylhydroxylamine, lithium hexamethyldisilazane, THF, rt, 1 h, 100%; (d) p-toluenesulfonic 
acid monohydrate, CH3OH, rt, overnight, 55%. 
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Scheme 2. Synthesis of compound 3. Reagents and conditions: a) EtONa, ethanol, rt, 1 h, 31%; b) 4-
formylphenylboronic acid, Pd(PPh3)4, Na2CO3 2M, toluene, reflux, 10 h, 87%; c) Ph3P=CHCOOEt, CHCl3, 
reflux, 8 h, 91%; d) trifluoroacetic acid, CH2Cl2, 0 °C, 2 h, 81%; e) LiOH·H2O, THF/H2O, rt, overnight, 
94%; f) hydroxylamine hydrochloride, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (WSC), 1-Hydroxybenzotriazole (HOBt), triethylamine, DMF, rt, 7 h, 97%. 
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2.2 HDAC inhibition, structural rationalization, and antiproliferative activity against human 
carcinoma cell lines   
 
Compounds were first tested for their general HDAC inhibitory activity, by using a Hela nuclear 
extract as a source of HDACs. Compounds 2 and 3 showed a slightly better activity than 1a, a 
compoud we have previously tested for HDAC inhibition [8] (Table 1). It is important to notice that 
when HeLa cells were treated with each compound, a HDAC inhibition was found in the same 
range as observed in the enzymatic assay. Compound 3 was the most active towards nuclear 
HDACs when compared to compound 1a and 2, probably due to the addition of the indole cap 
group [12].  
 
 
Table 1. HDAC2 inhibitory activity of compounds 1-3  
 
Compounds HeLa nuclear 
extract 
HDAC2 HeLa cell 
 
IC50 [µM] 
1a 32.6±3.7 1.2±0.27a 8.7±0.20 
2 2.6±0.38 11.8±2.0 2.5±0.18 
3 1.5±0.45 5.2±0.13 6.4±1.1 
SAHA 0.28±0.04 0.10±0.02 - 
 
   
Results are the mean ± SD of three independent experiments. 
a
 Ref. 8 
 
A binding mode was proposed for compounds 2 and 3: docking studies were carried out on HDAC2 
catalytic site (Figure 2). The molecular docking protocol was first validated through the re-docking 
of the co-crystallized SAHA within the HDAC2 protein structure. Docking calculations revealed 
the capability of the docking tool to retrieve the correct binding mode within HDAC2 [14]. For 
compound 2 (61 % convergent docking poses, best ranked pose: 77.4 ChemPLP score), a chelation 
of the zinc ion through the hydroxamate group was observed, as expected. The zinc binding portion 
of the molecule was further stabilized by polar contacts with Tyr308. Pi-pi stacking and van der 
Waals interactions with Phe155, Phe210, and Leu276 side chains, respectively, were also involved 
in the stabilization of the first phenyl ring of the linker portion, whereas the second ring was solvent 
exposed (Figure 2A). For compound 3 (Figure 2B, 60% convergent docking poses, best ranked 
pose: 89.7 ChemPLP score) the interaction network between the hydroxamate, the aromatic linker, 
and the protein was conserved just as for compound 2. However, the indole group of compound 3, 
characterizing the cap portion of the molecule, was further stabilized by hydrophobic interactions 
with Pro34, Phe155, and Leu276 side chains, thus increasing complex stability (Figure 2B).  
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A B 
Fig. 2. HDAC2 in complex with compound 2 (best-ranked pose, yellow balls & sticks, A), and compound 3 
(best-ranked pose, red balls & sticks, B). The protein is reported as green ribbons. Zinc ion is indicated as a 
gray ball. Residues involved in ligands stabilization are labeled.  
 
Compounds 2 and 3 were then tested for their antiproliferative activity against a panel of tumor cell 
lines of different tissue origin. Derivative 3 appeared to be the most promising compound when 
tested against  human ovarian carcinoma IGROV1, human lung carcinoma H460, human colon 
cancer cells HCT116 and human colon adenocarcinoma HT29 cell lines, exhibiting IC50 values in 
the range of 0.3- 1.4 µM. The antiproliferative activity on these cell lines is comparable or slightly 
better than the activity of the parent compound 1a and SAHA, a clinically approved pan-HDAC 
inhibitor (Table 2). Compound 3 was also tested on multidrug-resistant tumor cell lines: the subline 
of human colon adenocarcinoma cell line LoVo resistant to doxorubicin LoVo /DX, which 
expresses high levels of the P-glycoprotein; the subline of human colon adenocarcinoma cells HT29 
resistant to mitoxantrone HT29/MIT, which exhibited a high up-regulation of the breast carcinoma 
resistance protein BCRP. The compound exhibited antiproliferative effects against resistant sublines 
with IC50 values similar to those obtained in corresponding sensitive cell lines.  
 
Table 2. Antiproliferative activity (IC50, µM) of compounds 1a, 2, 3 and reference HDAC inhibitor (SAHA) 
against a panel of tumor cell lines. 
 
 
IGROV-1 H460 LoVo LoVo/DX HT29 HT29/MIT HCT116 
Cpd IC50 (µM) 
1a 0.75±0.40 3.7±0.1 ND ND 1.58±0.02 1.73±0.11 0.26±0.03 
2 2.5±1.09 5.5± 0.04 2.79±0.59 ND 4.12±0.08 ND 2.00±0.57 
3 0.35±0.06 1.41±0.09 6.57±0.78 4.62±0.03 1.37±0.76 2.44±0.34 0.27±0.07 
SAHA 2.2±0.3 3.4±0.8 3.7±0.5 ND ND ND 0.31±0.02 
Results are the mean ± SD of three independent experiments. 
N.D.: not determined. 
IC50 is defined as the drug concentration causing a 50% reduction of cell number compared with that of untreated sample. 
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Based on the enzymatic, structural, and antiproliferative results, compound 3 was chosen for further 
investigation. Protein acetylation, after 4 or 24 h of exposure to compound 3 and LAQ824, a pan-
HDAC inhibitor used as reference compound, was investigated in the ovarian carcinoma cells 
IGROV-1, one of the most sensitive cell lines in our panel (Figure 3). As expected, LAQ824 
induced a marked acetylation of histone H4, p53 and tubulin. Interestingly, under the same 
conditions, treatment with compound 3 increased the levels of acetylated tubulin. Since this effect is 
usually consistent with cytoplasmic HDAC6 isoform selectivity, a comparative study on the effects 
on different HDAC isoforms was also carried out (Table 3). 
 
 
Table 3. Inhibition of HDAC isoforms by compound 3a. 
 
 HDAC-1 HDAC-3 HDAC-4 HDAC-5 HDAC-6 HDAC-7 HDAC-8 HDAC-9 HDAC-10 HDAC-11 
IC50 (µM) 
SAHA 0.26 0.35 0.49 0.38 0.029 0.034 0.24 0.32 0.46 0.36 
3 5.4 3.9 17.1 8.0 1.0 10.9 0.58 8.9 10.2 16.2 
aAssay condition for compounds is to start with 50 µM, 1:3 dilution, 10 doses.  
 
According to Table 3, compound 3 can be considered as a pan-HDAC inhibitor for its capacity to 
inhibit all of the HDACs isoforms, with a preferential inhibition towards HDAC6 together with 
HDAC8.  
The inhibition of HDAC8 could be pharmacologically relevant, because this isoform is 
deregulated and overexpressed in tumor cells. Moreover, HDAC8 is known to interact with various 
transcription factors, including p53, and therefore implicated in modulation of apoptosis [15]  
Induction of apoptosis was thus examined for compound 3 following 72 h exposure (Figure 4). 
Compound 3 triggered apoptotic processes in IGROV-1 cells with the appearance of around 34% 
and 79% TUNEL-positive cells at IC50 and IC80, respectively. Interestingly, the compound was 
more effective as apoptosis inducer than SAHA under the same conditions (79% vs 37% at 
equitoxic  concentrations, IC80) [10]. 
The marked cell death response to the treatment was also consistent with the presence of a large 
sub-G1 peak (Figure 4). Moreover, the exposure of this compound strongly promoted cell cycle 
arrest primarily at the G1 phase (Figure 4). The potent proapoptotic activity of 3 could be consistent 
with HDAC8 inhibition. 
The in vivo antitumor activity of 3 was examined in the colon carcinoma xenograft HCT116. A 
daily oral administration (5 days/week) for 4 weeks produced a significant tumor growth inhibition 
(68%, p<0.01, Figure 5). The antitumor efficacy of 3 was more persistent than  SAHA (48% tumor 
growth inhibition) as indicated by the tumor growth delay following the end of treatment. The 
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antitumor efficacy is consistent with the expected responsiveness of the tumor model (HCT116) to 
HDAC inhibitors. However, we cannot rule out other off-target effects. 
 
 
 
Fig. 3. Effects of compound 3 and LAQ824 (reference compound) on acetylation of tubulin, histone H4 and 
p53 in IGROV-1 cells. Cells were treated for 24h with equitoxic (1µM compound 3 and 0.2 µM LAQ824, 
corresponding to IC80 value) and equimolar concentration values (0.2µM). Cell lysates were prepared and 
examined by western-blot analysis. The blots were reprobed with β-tubulin as a loading control. 
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Fig. 4. Flow cytometric analysis of apoptosis and cell cycle perturbation induced after the exposure to 
compound 3 (IC80 and IC50 value) in ovarian carcinoma cells IGROV-1.. a) The extent of apoptosis was 
determined 72 h after drug exposure by TUNEL assay. b) Time course analysis of cell cycle was performed 
by propidium-iodide staining. 
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Fig. 5. Antitumor effect of compound 3 and SAHA against the human colon carcinoma HCT116. Animals 
were treated with once daily administration for 5 days a week for 4 weeks by oral route with 175 mg/kg. 
Control refers to animals treated with solvent only. 
 
3. Conclusions 
 
In an effort to improve the pattern of HDAC inhibitory activity of biphenyl-4-yl-acrylohydroxamic 
acids, we have identified two new structures with branching points in the biphenyl system. The best 
candidate, 3, showed HDAC inhibition and antiproliferative activity on a panel of tumor cell lines 
in the low µM range. The compound was further tested in vitro for acetylation of H4 histone and 
other target proteins, and in vivo in a colon carcinoma model, showing promising proapoptotic and 
antitumor activities.  
Due to its in vitro as well as in vivo activity profile, compound 3 represents an interesting starting 
point for the design of next generation HDAC inhibitors. Docking studies of compounds 3 and 1a in 
HDAC2 catalytic site, showed that the indole moiety gave additional hydrophobic interactions with 
the aminoacids in the pocket, thus increasing the complex stability. Functionalization of this more 
versatile scaffold could provide further favourable interactions with the perspective of enhancing 
target inhibition and pharmacological efficacy.  
 
4. Experimental section 
 
4.1. Chemistry 
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All reagents and solvents were reagent grade or were purified by standard methods before use. 
Melting points were determined in open capillaries and are uncorrected. NMR spectra were 
recorded in CDCl3 (where not otherwise stated) at 300 MHz. Chemical shifts (δ values) and 
coupling constants (J values) are given in ppm and Hz, respectively. Solvents were routinely 
distilled prior to use; anhydrous tetrahydrofuran (THF) and ether (Et2O) were obtained by 
distillation from sodium-benzophenone ketyl; dry methylene chloride was obtained by distillation 
from phosphorus pentoxide. All reactions requiring anhydrous conditions were performed under a 
positive nitrogen flow, and all glassware were oven dried and/or flame dried. Isolation and 
purification of the compounds were performed by flash column chromatography on silica gel 60 
(230-400 mesh). Analytical thin-layer chromatography (TLC) was conducted on Fluka TLC plates 
(silica gel 60 F254, aluminum foil).  
 
4.2. 1-Bromo-4-(2-methyl-1-phenyl-1-propen-1-yl)-benzene (5). 
TiCl4 (1.66 mL, 15.3 mmol) was added to a stirred suspension of zinc powder (1.99 g, 30.6 mmol) 
in dry THF (34 mL), under nitrogen, at -10 °C. When the addition was complete, the mixture was 
warmed to room temperature and then refluxed for 2 h. To the cooled suspension of the titanium 
reagent was added a solution of 4-bromobenzophenone (1.00 g, 3.82 mmol) and acetone (0.33g,  
0.84 mL, 11.46 mmol) in dry THF (70 mL) at 0 °C, and the mixture was refluxed in the dark for 2.5 
h, then it was stirred overnight at room temperature. The reaction mixture was poured into 10% 
aqueous potassium carbonate and extracted with EtOAc. The organic layer was washed with brine, 
dried (Na2SO4), and concentrated in vacuo. Flash column chromatography (hexane/ethyl acetate 
8:2) afforded 5 as a colorless oil. Yield 71%. 1H NMR (CDCl3) δ: 7.39 (d, 2H, J = 8.3 Hz), 7.32-
7.10 (m, 4H), 7.00 (d, 1H, J = 8.3 Hz), 1.81 (s, 6H). Anal. calcd for C16H15Br: C, 66.91; H, 5.26. 
Found: C, 66.99; H, 5.24. 
 
4.3. 3-[4-(2-Methyl-1-phenyl-propenyl)-phenyl]-acrylic acid methyl ester (6). 
A mixture of 5 (267 mg, 0.93 mmol), acrylic acid methyl ester (127 mg, 1.48 mmol), Pd(II) acetate 
(2 mg, 0.009 mmol), tri(o-tolyl)phosphine (11 mg, 0.037 mmol) and triethylamine (539 mg, 5.33 
mmol) were refluxed for 3h. After cooling to room temperature, the solution was poured into water, 
acidified with 3N HCl and extracted with ethyl acetate. The organic phase was dried over Na2SO4 
and evaporated under reduced pressure. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 9:1) to give 110 mg of the title compound as an oil. Yield 40%. 1H NMR 
(CDCl3) δ: 7.68 (d, 1H, J = 15.8 Hz), 7.43 (d, 2H, J = 8.3 Hz), 7.35-7.00 (m, 7H), 6.80 (d, 1H, J = 
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15.8 Hz), 3.80 (s, 3H), 1.85 (s, 3H), 1.81 (s, 3H). Anal. calcd for C20H20O2: C, 82.16; H, 6.89. 
Found: C, 82.39; H, 6.87.  
 
4.4. 3-[4-(2-Methyl-1-phenyl-propenyl)-phenyl]-N-(tetrahydropyran-2-yloxy)-acrylamide (7). 
Compound 6 (110 mg, 0.37 mmol), was dissolved in 5 mL of anhydrous THF, then O-
tetrahydropyranylhydroxylamine (43 mg, 0.37 mmol) was added. The solution was cooled to -78 °C 
and treated with 0.75 mL (0.77 mmol) of lithium hexamethyldisilazane. The mixture was stirred for 
1 h under nitrogen, then was quenched  with NH4Cl solution. Once at room temperature, the 
mixture was extracted with ethyl acetate and the organic phase was dried over Na2SO4. The solvent 
was evaporated under reduced pressure to give 139 mg of the desired compound as an pale yellow 
oil. Yield 100%. 1H NMR (CDCl3) δ : 8.36 (s, 1H), 7.71 (d, 1H, J = 15.7 Hz), 7.46 (d, 2H, J = 8.3 
Hz), 7.36-7.00 (m, 8H), 6.37 (brs, 1H), 5.13-4.88 (m, 1H), 4.05-3.85 (m, 1H), 3.77-3.55 (m, 1H), 
1.82 (s, 3H), 1.76 (s, 3H), 1.71-1.46 (m, 6H). Anal. calcd for C24H27NO3: C, 76.36; H, 7.21; N, 
3.71. Found: C, 76.21; H, 7.19; N, 3.72.  
 
4.5. N-Hydroxy-3-[4-(2-methyl-1-phenyl-propenyl)-phenyl]-acrylamide (2). 
Compound 7 (60 mg, 0.17 mmol) was dissolved in 1.8 mL of methanol, then p-toluenesulfonic acid 
monohydrate (9 mg, 0.005 mmol) was added. The mixture was stirred overnight at room 
temperature. The solvent was concentrated and the solid formed was filtered and washed with water 
to afford 27 mg of the title compound as a white solid. Yield 55%, M.p. 186-187°C. 1H NMR 
(DMSO-d6) δ: 10.78 (s, 1H), 9.05 (brs, 1H), 7.57-7.38 (m, 3H), 7.36-7.20 (m, 3H), 7.17-7.05 (m, 
4H), 7.42 (d, 1H, J = 15.7 Hz).  
13C NMR (DMSO-d6) δ: 163.2, 144.4, 142.9, 138.5, 136.6, 133.2, 131.6, 130.4, 129.9 (× 2), 128.5 
(× 2), 127.7, 126.8, 119.1, 22.7, 22.6. Anal. calcd for C19H19NO2: C, 77.79; H, 6.53; N, 4.77. 
Found: C, 77.57; H, 6.55; N, 4.79.  
 
4.6. (E)-3-[2-(2-Bromo-phenyl)-vinyl]-1-tert-butyloxycarbonyl-2-methyl-indole (10). 
To a solution of EtONa (1.2 g, 18.33 mmol) in ethanol (54 mL), (2-
bromobenzyl)triphenylphosphonium bromide [16] (9.79 g, 19.13 mmol) was slowly added and the 
mixture was stirred at room temperature for 3 h. After cooling at 0 °C, 3-formyl-2-methyl-indole-1-
carboxylic acid tert-butyl ester [117] (4 g, 15.43 mmol) was added portionwise and the stirring was 
continued for 1h at room temperature. The solution was poured into 1N HCl and extracted with 
diethyl ether (× 3). The organic phase was washed with brine, dried over Na2SO4 and evaporated 
under reduced pressure. The residue was purified by crystallization from ethyl ether/hexane to 
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afford 1.96 g of the desired compound as a white solid. Yield 31%. 1H NMR (DMSO-d6) δ: 8.19-
8.10 (m, 1H), 8.06-7.89 (m, 2H), 7.68 (d, 1H, J = 8.49 Hz), 7.52-7.31 (m, 5H), 7.22 (t, 1H, J = 7.25 
Hz), 2.71 (s, 3H), 1.67 (s, 9H). Anal. calcd for C22H22BrNO2: C, 64.09; H, 5.38; N, 3.40. Found: C, 
64.28; H, 5.39; N, 3.38.  
 
4.7. (E)-3-[2-(4’-formyl-biphenyl-2-yl)-vinyl]- 1-tert-butyloxycarbonyl 2-methyl-indole- (11). 
Compound 10 (1.91 g, 4.68 mmol) was dissolved in toluene, then 2M Na2CO3 (4.68 mL), Pd(PPh3)4 
(162 mg, 0.140 mmol) and 4-formylphenylboronic acid (789 mg, 5.15 mmol) were added under 
nitrogen and the mixture was refluxed for 10 h. After cooling to room temperature, ethyl acetate 
was added and the organic phase was washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure. The crude product was purified by flash chromatography (hexane/ethyl acetate 
90:10) to give 1.79 g of the title compound as a white solid. Yield 87%. M.p. 102°C. 1H NMR 
(CDCl3) δ: 10.15 (s, 1H), 8.15 (d, 1H, J = 7.4 Hz), 7.98 (d, 2H, J = 8.20 Hz), 7.87 (d, 1H, J = 7.7 
Hz), 7.67 (d, 2H, J = 8.20 Hz), 7.59-7.38 (m, 4H), 7.31-7.00 (m, 4H), 2.69 (s, 3H), 1.71 (s, 9H). 
Anal. calcd for C29H27NO3: C, 79.61; H, 6.22; N, 3.20. Found: C, 79.88; H, 6.18; N, 3.18.  
 
4.8.(E,E)-3-{2-[4’-(2-ethoxycarbonyl-vinyl)-biphenyl-2-yl]-vinyl}-1-tert-butyloxycarbonyl -2-
methylindole (12). 
Compound 11 (1.74 g, 3.98 mmol) was dissolved in chloroform (21 mL) under nitrogen, then 
(carbethoxymethylidene)triphenylphosphorane (1.39 g, 3.98 mmol) was added and the mixture was 
refluxed for 8 h. The solvent was evaporated and the residue was purified by flash chromatography 
(hexane/diethyl ether 90:10) to give 1.82 g of the title compound as a yellow solid. Yield 91%. M.p. 
62-63 °C. 1H NMR (CDCl3) δ: 8.14 (d, 1H, J = 7.4 Hz), 7.89-7.70 (m, 2H), 7.61 (d, 2H, J = 8.20 
Hz), 7.58-7.35 (m, 7H), 7.31-7.08 (m, 3H), 6.50 (d, 1H, J = 16.50 Hz), 4.30 (q, 2H, J = 7.1 Hz), 
2.68 (s, 3H), 1.71 (s, 9H), 1.39 (t, 3H, J = 7.1 Hz). Anal. calcd for C33H33NO4: C, 78.08; H, 6.55; N, 
2.76. Found: C, 78.18; H, 6.57; N, 2.74.  
 
4.9. (E,E)-3-{2’-[2-(2-methyl-1H-indol-3-yl)-vinyl]-biphenyl-4-yl}-acrylic acid ethyl ester (13). 
Compound 12 (1.61 g, 3.18 mmol) was dissolved in dry dichloromethane (31.8 mL) and the 
solution was cooled to 0 °C. Trifluoroacetic acid (31.8 mL) was slowly dropped and the mixture 
was stirred at 0 °C for 2 h. The solvent was evaporated under reduce pressure, the residue was 
diluted with diethyl ether and washed with sodium bicarbonate. The organic phase was dried over 
Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by flash 
chromatography (hexane/acetone 70:20) to afford 1.05 g of the desired compound. Yield 81%. M.p. 
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110 °C. 1H NMR (CDCl3) δ: 7.98 (s, 1H), 7.87-7.72 (m, 2H), 7.68-7.49 (m, 5H), 7.48-7.20 (m, 3H), 
7.18-6.98 (m, 3H), 6.50 (d, 1H, J = 16.50 Hz), 4.31 (q, 2H, J = 7.1 Hz), 2.51 (s, 3H), 1.39 (t, 3H, J 
= 7.1 Hz).  Anal. calcd for C28H25NO2: C, 82.53; H, 6.18; N, 3.44. Found: C, 82.40; H, 6.20; N, 
3.43.  
 
4.10. (E,E)-3-{2’-[2-(2-methyl-1H-indol-3-yl)-vinyl]-biphenyl-4-yl}-acrylic acid (14) 
Compound 13 (2.15 g, 5.28 mmol) was dissolved in a solution of 1.1 g (26.4 mmol) of LiOH·H2O 
in 247 mL of THF/H2O 1:1 and the mixture was stirred overnight at room temperature in the dark. 
THF was evaporated and the aqueous phase was acidified with 1N HCl. The solid formed was 
filtered and dried to give 1.87 g of the desired compound as a yellow solid. Yield 94%. M.p. 129-
130 °C; 1H-NMR (300 MHz, DMSO-d6) δ: 12.45 (brs, 1H), 11.22 (s, 1H), 7.91 (d, 1H, J = 7.4 Hz), 
7.82 (d, 2H, J = 8.20 Hz), 7.69 (d, 1H, J = 16.50 Hz), 7.52-7.22 (m, 8H), 7.08-6.82 (m, 3H), 6.60 
(d, 1H, J = 16.50 Hz), 2.43 (s, 3H). Anal. calcd for C26H21NO2: C, 82.30; H, 5.55; N, 3.67. Found: 
C, 82.50; H, 5.43; N, 3.44.  
 
4.11. (E,E)-N-Hydroxy-3-{2’-[2-(2-methyl-1H-indol-3-yl)-vinyl]-biphenyl-4-yl}-acrylamide (3). 
Compound 14 (1.86 g, 4.92 mmol) was dissolved in 56 mL of DMF, then 1-hydroxybenzotriazole 
(HOBt) (1.16 g, 7.38 mmol) was added in one portion followed by N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (WSC) (1.54 g, 7.87 mmol) and the mixture was stirred at room 
temperature for 5 h in the dark. To the orange solution hydroxylamine hydrochloride (1.7 g, 24.6 
mmol) and  triethylamine (3.41 mL, 24.6 mmol) were added and the stirring was continued for 2h. 
The suspension was diluted with water (250 mL), filtered and the solid was washed with water to 
afford 1.89 g of the desired compound as a yellow sticky solid. Yield 97%. 1H NMR (DMSO-d6) δ: 
11.25 (s, 1H), 10.81 (brs, 1H), 9.08 (brs, 1H), 7.91 (d, 1H, J = 7.4 Hz), 7.70 (d, 2H, J = 7.5 Hz), 
7.63-7.21 (m, 9H), 7.15-6.75 (m, 3H), 6.55 (d, 1H, J = 16.50 Hz), 2.43 (s, 3H). 13C NMR (DMSO-
d6) δ: 163.1, 142.5, 139.3, 138.3, 136.8 (× 2), 136.1, 134.1, 130.6 (× 2), 130.2, 128.3, 127.8 (× 2), 
126.7, 126.2, 125.0, 123.7, 121.6, 121.3, 120.0, 119.6, 199.0, 111.5, 110.2, 12.2. Anal. calcd for 
C26H22N2O2: C, 79.16; H, 5.62; N, 7.10. Found: C, 79.04; H, 5.60; N, 7.08.  
 
4.12. Enzymatic assays 
Compounds were tested for HDAC inhibition on HeLa nuclear extract (Enzo Life Sciences, Lausen, 
Switzerland) and HDAC2 (Sigma-Aldrich, Buchs, Switzerland). Reactions were carried out in 96-
well ½ volume microplates. The HeLa nuclear extract or specific isoform were diluted in assay 
buffer (50 mM Tris at pH 8.0 adjusted with HCl, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) and 
added to each microplate well, except for blanks. Test compounds were diluted in DMSO and 
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added to 100 µM (5% DMSO in each well) for screening purposes. The reaction was initiated by 
the addition of BOC-Ac-Lys-AMC substrate for HeLa nuclear extract or the Fluor de Lys™ Green 
substrate (BML-KI572, Enzo) for HDAC2. The plate was then incubated at 37°C for 90 min (HeLa 
nuclear extract) or 30 min (HDAC2). The reaction was stopped with 1 µM Trichostatin A. Trypsin 
from bovine pancreas, 7500 BAEE units/mg (Sigma-Aldrich) was added 30 min prior to plate 
reading. HDAC inhibition was calculated by comparing the amount of deacetylated substrate 
between control (100% HDAC activity) and test sample. The relative amount of deacetylated 
substrate was obtained by fluorescence reading with excitation at 360 nm and emission at 460 nm 
for HeLa nuclear extract. Excitation at 485 nm and emission at 528 nm were used for HDAC2. 
Dose-response curves were obtained with 6 different concentrations to determine the IC50 values of 
active compounds. Results are the mean of three independent experiments. Trichostatin A was used 
as positive control. 
 
4.13. Histone Deacetylase Profiling (HDAC1, HDAC3-11) 
HDAC profiling was performed by Reaction Biology Corp. (Malvern, PA) against 10 isolated 
isoforms of human HDAC (HDAC1, HDAC3-11) in the presence of the fluorogenic tetrapeptide 
RHKKAc (p53 residues 379-382) as the substrate (50 μM). Isolated human HDACs were obtained 
by standard purification, with the exception of HDAC3, which was isolated in complex with 
NCOR2 and used as such. SAHA was used as reference compound. Each compound was dissolved 
in DMSO (1:3 diluition; 10 doses), and sequentially diluted solutions were used for testing. IC50 
values were calculated from the resulting sigmoidal dose-response inhibition slopes. 
 
4.14. Cell-based assay 
HeLa cells (American Type Culture Collection (ATCC), Rockville, MD) were plated in 96-well 
plates at a density of 6,000 cells per well and maintained in Minimum Essential Medium (Life 
Technologies, Zug, Switzerland), supplemented with 10% fetal calf serum, penicillin G (100 U/mL) 
and streptomycin (100 μg/mL) at 37 °C in a humidified atmosphere of 5% CO2 in air, for 24 h. Cells 
were then treated with test samples diluted in DMSO at six different concentrations (0.5% DMSO 
in assay well) together with BOC-Ac-Lys-AMC substrate at 21.0 µM. The plate was then incubated 
at 37°C for 4 h. The reaction was stopped by the addition of lysis buffer (1 µM, Trichostatin A, 1%, 
Igepal CA-630, 50 mM, Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2), trypsin was 
added and the experiment was finished as described above. The relative amount of deacetylated 
substrate was obtained by fluorescence reading (460/360 nm). Results are the mean of three 
independent experiments. Trichostatin A was used as positive control. 
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4.15. Molecular docking 
Molecular docking calculations were carried out with GOLD version 5.2 (CCDC Cambridge). The 
three-dimensional structure of HDAC2 was taken from the Protein Data Bank (PDB id: 4LXZ). 
From this protein, water molecules and the co-crystallized ligand were removed whereas hydrogen 
atoms were added using Sybyl-X 1.3 (Tripos Inc.). Ligands for docking were also prepared using 
Sybyl-X 1.3, checking atom and bond types together with protonation states. The active site was 
then defined by selecting HDAC2 residues within 6 Å from the co-crystallized ligand. Trigonal 
bipyramid geometry for the zinc ion was defined. ChemPLP score was used for ranking the one 
hundred docking poses generated for each ligand. The rmsd_analysis tool of GOLD was finally 
used for cluster analysis within a cut-off of 2 Å. Images were generated with Sybyl-X 1.3 (Tripos 
Inc.). 
 
4.16. Cellular sensitivity to test compounds 
Cellular sensitivity to test compounds was evaluated by growth-inhibition assay after 72-h drug 
exposure. Cells in the logarithmic phase of growth were seeded in duplicate into 6-well plates. 
Twenty-four hours after seeding, the test compound was added to the medium. Cells were harvested 
72 h after drug exposure and counted with a cell counter. IC50 is defined as the drug concentration 
causing a 50% reduction of cell number compared with that of untreated control. 
 
4.17. Cell cycle analysis 
The cell cycle distribution was analyzed in propidium iodide stained cells by FACScan flow 
cytometry (Becton Dickinson), as described previously [18]. 
 
4.18. TUNEL assay 
Apoptosis was determined in ovarian carcinoma IGROV-1 cells by TUNEL assay following 72 h-
exposure to the drug and fixed in 4% paraformaldehyde for 45 min, at room temperature. The in 
situ cell death detection kit fluorescein (Roche, Mannheim, Germany) was used according to 
manufacturers’ instructions. Samples were analyzed by FACScan flow cytometry (Becton 
Dickinson). 
 
4.19. Western blotting 
Cells treated with various concentrations of HDAC inhibitors for 4 h were collected and lysed as 
previously described [18]. 
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4.20. Tumor models and evaluation of antitumor activity  
The experiments were performed using female athymic Swiss nude mice. Mice were maintained in 
laminar flow rooms keeping temperature and humidity constant. Mice had free access to food and 
water. Experiments were approved by the Ethics Committee for Animal Experimentation of the 
Istituto Nazionale Tumori of Milan according to institutional guidelines. 
Exponentially growing tumor cells (107 cells/mouse) were s.c. injected into the right flank of 
athymic nude mice. Tumor lines were achieved by serial s.c. passages of fragments (about 2 × 2 × 6 
mm) from growing tumors into healthy mice. Animals were treated 3 days after tumor implantation. 
Compounds were dissolved in DMSO and diluted in PBS containing 5% Cremophor to a final 
concentration of 10% DMSO. 
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